Novel prime-boost vaccine strategies against HIV-1
Introduction: Given the complexities of HIV infection and the HIV genetic heterogeneity, a successful HIV vaccine should elicit broad adaptive and innate immune responses. Vaccine prime-boost platforms may achieve this goal. Several factors including selection of antigen, type of vector, delivery ro...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-08-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2019.1640117 |
| _version_ | 1797680333297025024 |
|---|---|
| author | Jean-Louis Excler Jerome H. Kim |
| author_facet | Jean-Louis Excler Jerome H. Kim |
| author_sort | Jean-Louis Excler |
| collection | DOAJ |
| description | Introduction: Given the complexities of HIV infection and the HIV genetic heterogeneity, a successful HIV vaccine should elicit broad adaptive and innate immune responses. Vaccine prime-boost platforms may achieve this goal. Several factors including selection of antigen, type of vector, delivery route, dose, adjuvant, boosting regimen, order of vector injection, and intervals between vaccinations influence the outcome. Areas covered: We reviewed the literature on the latest findings of the various prime-boost HIV vaccine clinical trials, with particular emphasis on the most advanced and promising strategies. Expert opinion: Data suggest that heterologous may be better than homologous prime-boost regimens for protection. The most advanced strategies to have reached efficacy trials use either canarypox vector (ALVAC) boosted by adjuvanted gp120 protein or adenovirus (Ad26) vector expressing mosaic antigens boosted by gp140 protein. DNA prime and vectors and/or protein boost regimens are at less advanced development stage. These regimens, while imperfect (efficacy ≥50%), could contribute substantially to the control of HIV epidemics as a part of a comprehensive HIV prevention program. To ensure prompt vaccine access in populations with the greatest need, attention should be given to post-efficacy activities necessary to achieve appropriate uptake and implementation of effective vaccines. |
| first_indexed | 2024-03-11T23:28:28Z |
| format | Article |
| id | doaj.art-064afb1fdd034ff983a1683b368455a2 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:28:28Z |
| publishDate | 2019-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-064afb1fdd034ff983a1683b368455a22023-09-20T10:18:04ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952019-08-0118876577910.1080/14760584.2019.16401171640117Novel prime-boost vaccine strategies against HIV-1Jean-Louis Excler0Jerome H. Kim1International Vaccine InstituteInternational Vaccine InstituteIntroduction: Given the complexities of HIV infection and the HIV genetic heterogeneity, a successful HIV vaccine should elicit broad adaptive and innate immune responses. Vaccine prime-boost platforms may achieve this goal. Several factors including selection of antigen, type of vector, delivery route, dose, adjuvant, boosting regimen, order of vector injection, and intervals between vaccinations influence the outcome. Areas covered: We reviewed the literature on the latest findings of the various prime-boost HIV vaccine clinical trials, with particular emphasis on the most advanced and promising strategies. Expert opinion: Data suggest that heterologous may be better than homologous prime-boost regimens for protection. The most advanced strategies to have reached efficacy trials use either canarypox vector (ALVAC) boosted by adjuvanted gp120 protein or adenovirus (Ad26) vector expressing mosaic antigens boosted by gp140 protein. DNA prime and vectors and/or protein boost regimens are at less advanced development stage. These regimens, while imperfect (efficacy ≥50%), could contribute substantially to the control of HIV epidemics as a part of a comprehensive HIV prevention program. To ensure prompt vaccine access in populations with the greatest need, attention should be given to post-efficacy activities necessary to achieve appropriate uptake and implementation of effective vaccines.http://dx.doi.org/10.1080/14760584.2019.1640117hiv vaccineprime-boostviral vectoralvacad26mosaicenvelope proteinefficacyimmune correlates of risk |
| spellingShingle | Jean-Louis Excler Jerome H. Kim Novel prime-boost vaccine strategies against HIV-1 Expert Review of Vaccines hiv vaccine prime-boost viral vector alvac ad26 mosaic envelope protein efficacy immune correlates of risk |
| title | Novel prime-boost vaccine strategies against HIV-1 |
| title_full | Novel prime-boost vaccine strategies against HIV-1 |
| title_fullStr | Novel prime-boost vaccine strategies against HIV-1 |
| title_full_unstemmed | Novel prime-boost vaccine strategies against HIV-1 |
| title_short | Novel prime-boost vaccine strategies against HIV-1 |
| title_sort | novel prime boost vaccine strategies against hiv 1 |
| topic | hiv vaccine prime-boost viral vector alvac ad26 mosaic envelope protein efficacy immune correlates of risk |
| url | http://dx.doi.org/10.1080/14760584.2019.1640117 |
| work_keys_str_mv | AT jeanlouisexcler novelprimeboostvaccinestrategiesagainsthiv1 AT jeromehkim novelprimeboostvaccinestrategiesagainsthiv1 |